Sevion is dedicated to developing innovative product candidates for cancer and immunological diseases. Leveraging its unique antibody technology platforms, the company is advancing a pipeline of proprietary and partnered product candidates. Sevion's antibody pipeline is being developed from technology that allows for the discovery of biologic therapies to previously inaccessible targets, including multispanning membrane proteins and ion channels that play a crucial role in multiple diseases. Additionally, the company has developed the first protein nanocage system, which allows for the delivery of nucleic acids and other payloads to target cells. Sevion is a provider of pharmaceutical research services and is committed to developing products and technologies for human therapeutic applications to treat cancer and inflammatory diseases in the United States.